Published technology appraisals

This table lists published NICE technology appraisals. The list can be sorted by title (alphabetically), issue date and review date. You can also:

  • click the appraisal title for full details
  • click a column heading to sort the list by that column

Please note that the 'review date' is not the date when a review of it the appraisal starts, but the date NICE consults on a proposal for reviewing it. There is no guarantee that at the review date, a review will be undertaken. Appraisals which have been considered for review and where the decision has been not to carry out a review at this time are listed in static technology appraisals.

More information on the published appraisals list.

For technology appraisal guidance organised by category, use Find guidance in the main header area above.

Searching for specific technology appraisal guidance?

Published appraisals

Ref Title Date Issued Review
TA311 Multiple myeloma - bortezomib (induction therapy) (TA311) Apr 2014 Apr 2017
TA310 Lung cancer (non small cell, EGFR mutation positive) - afatinib (TA310) Apr 2014 Apr 2017
TA309 Lung cancer (non small cell, non squamous) - pemetrexed (TA309) Apr 2014 Apr 2017
TA308 Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with glucocorticoids) (TA308) Mar 2014 Mar 2017
TA307 Colorectal cancer (metastatic) - aflibercept (TA307) Mar 2014 Aug 2016
TA306 Lymphoma (non Hodgkin's, relapsed, refractory) - pixantrone monotherapy (TA306) Feb 2014 Nov 2016
TA305 Macular oedema (central retinal vein occlusion) - aflibercept solution for injection (TA305) Feb 2014 Feb 2017
TA304 Arthritis of the hip (end stage) - hip replacement (total) and resurfacing arthroplasty (Rev TA2, TA44) (TA304) Feb 2014 Feb 2017
TA303 Multiple sclerosis (relapsing) - teriflunomide (TA303) Jan 2014 TBC
TA302 Juvenile idiopathic arthritis (systemic) - canakinumab (terminated appraisal) (TA302) Nov 2013 TBC
TA301 Diabetic macular oedema - fluocinolone acetonide intravitreal implant (rapid review of TA271) (TA301) Nov 2013 Nov 2016
TA300 Hepatitis C (children and young people) - peginterferon alfa and ribavirin (TA300) Nov 2013 Sep 2016
TA299 Leukaemia (chronic myeloid) - bosutinib (TA299) Nov 2013 Jun 2016
TA298 Choroidal neovascularisation (pathological myopia) - ranibizumab (TA298) Nov 2013 Mar 2016
TA297 Vitreomacular traction - ocriplasmin (TA297) Oct 2013 Oct 2016
TA296 Lung cancer (non-small-cell, anaplastic lymphoma kinase fusion gene, previously treated) - crizotinib (TA296) Sep 2013 May 2016
TA295 Breast cancer (HER2 negative, oestrogen receptor positive, locally advanced or metastatic) - everolimus (with an aromatase inhibitor) (TA295) Aug 2013 Jun 2016
TA294 Macular degeneration (wet age-related) - aflibercept (TA294) Jul 2013 Feb 2014
TA293 Thrombocytopenic purpura - eltrombopag (TA293) Jul 2013 Mar 2014
TA292 Bipolar disorder (adolescents) - aripiprazole (TA292) Jul 2013 Jul 2017
TA291 Gout (tophaceous, severe debilitating, chronic) - pegloticase (TA291) Jun 2013 May 2016
TA290 Overactive bladder - mirabegron (TA290) Jun 2013 TBC
TA289 Myelofibrosis (splenomegaly, symptoms) - ruxolitinib (TA289) Jun 2013 Jun 2014
TA288 Type 2 diabetes - Dapagliflozin combination therapy (TA288) Jun 2013 Dec 2014
TA287 Pulmonary embolism and recurrent venous thromboembolism - rivaroxaban (TA287) Jun 2013 May 2015
TA286 Schizophrenia or bipolar disorder - loxapine inhalation (terminated appraisal) (TA286) May 2013 TBC
TA285 Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab (TA285) May 2013 Jun 2016
TA284 Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer (TA284) May 2013 Apr 2016
TA283 Macular oedema (retinal vein occlusion) - ranibizumab (TA283) May 2013 Mar 2016
TA282 Idiopathic pulmonary fibrosis - pirfenidone (TA282) Apr 2013 TBC
TA281 Gout - canakinumab (terminated appraisal) (TA281) Apr 2013 Jan 2100
TA280 Rheumatoid arthritis - abatacept (2nd line) (rapid review of TA234) (TA280) Apr 2013 Jan 2100
TA279 Vertebral fractures - vertebroplasty and kyphoplasty (TA279) Apr 2013 Nov 2015
TA278 Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201) (TA278) Apr 2013 Mar 2016
TA277 Methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care (terminated appraisal) (TA277) Mar 2013 Jan 2100
TA276 Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin (TA276) Mar 2013 Dec 2015
TA275 Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban (TA275) Feb 2013 Jan 2100
TA274 Macular oedema (diabetic) - ranibizumab (TA274) Feb 2013 Feb 2015
TA273 Hyperplasia (benign prostatic) - tadalafil (terminated appraisal) (TA273) Jan 2013 Jan 2100
TA272 Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine (TA272) Jan 2013 Nov 2015
TA271 Diabetic macular oedema - fluocinolone acetonide intravitreal implant (TA271) (replaced by TA301) Jan 2013 Nov 2015
TA270 Leukaemia (acute myeloid ) - decitabine (terminated appraisal) (TA270) Dec 2012 Jan 2100
TA269 Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib (TA269) Dec 2012 Nov 2014
TA268 Melanoma (stage III or IV) - ipilimumab (TA268) Dec 2012 Nov 2014
TA267 Chronic heart failure - ivabradine (TA267) Nov 2012 Nov 2015
TA266 Cystic fibrosis - mannitol dry powder for inhalation (TA266) Nov 2012 Oct 2015
TA265 Bone metastases from solid tumours - denosumab (TA265) Oct 2012 Jul 2013
TA264 Stroke (acute, ischaemic) - alteplase (TA264) Sep 2012 Sep 2015
TA263 Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (TA263) Aug 2012 Jun 2015
TA262 Ulcerative colitis (moderate to severe, second line) - adalimumab (terminated appraisal) (TA262) Jul 2012 Jan 2100
TA261 Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban (TA261) Jul 2012 May 2015
TA260 Migraine (chronic) - botulinum toxin type A (TA260) Jun 2012 Jun 2015
TA259 Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy) (TA259) Jun 2012 Apr 2015
TA258 Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line) (TA258) Jun 2012 TBC
TA257 Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor) (TA257) Jun 2012 Jun 2015
TA256 Atrial fibrillation (stroke prevention) - rivaroxaban (TA256) May 2012 Oct 2014
TA255 Prostate cancer - cabazitaxel (TA255) May 2012 Feb 2015
TA254 Multiple sclerosis (relapsing-remitting) - fingolimod (TA254) Apr 2012 TBC
TA253 Hepatitis C (genotype 1) - boceprevir (TA253) Apr 2012 Apr 2015
TA252 Hepatitis C (genotype 1) - telaprevir (TA252) Apr 2012 Apr 2015
TA251 Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib (TA251) Apr 2012 May 2014
TA250 Breast cancer (advanced) - eribulin (TA250) Apr 2012 Nov 2014
TA249 Atrial fibrillation - dabigatran etexilate (TA249) Mar 2012 Oct 2014
TA248 Diabetes (type 2) - exenatide (prolonged release) (TA248) Feb 2012 May 2012
TA247 Rheumatoid arthritis - tocilizumab (rapid review TA198) (TA247) Feb 2012 Jun 2013
TA246 Venom anaphylaxis - immunotherapy pharmalgen (TA246) Feb 2012 Jan 2017
TA245 Venous thromboembolism - apixaban (hip and knee surgery) (TA245) Jan 2012 Jan 2015
TA244 Chronic obstructive pulmonary disease - roflumilast (TA244) Jan 2012 TBC
TA243 Follicular lymphoma - rituximab (review) (TA243) Jan 2012 May 2014
TA242 Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review) (TA242) Jan 2012 Jan 2015
TA241 Leukaemia (chronic myeloid) - dasatinib, nilotinib, imatinib (intolerant, resistant) (TA241) Jan 2012 Sep 2014
TA240 Colorectal cancer (metastatic) - panitumumab (terminated appraisal) (TA240) Dec 2011 TBC
TA239 Breast cancer (metastatic) - fulvestrant (TA239) Dec 2011 Aug 2014
TA238 Arthritis (juvenile idiopathic, systemic) - tocilizumab (TA238) Dec 2011 TBC
TA237 Macular oedema (diabetic) - ranibizumab (TA237) (replaced by TA274) Nov 2011 Mar 2013
TA236 Acute coronary syndromes - ticagrelor (TA236) Oct 2011 Mar 2013
TA235 Osteosarcoma - mifamurtide (TA235) Oct 2011 Nov 2013
TA234 Rheumatoid arthritis - abatacept (2nd line) (TA234) (replaced by TA280) Aug 2011 Jul 2014
TA233 Ankylosing spondylitis - golimumab (TA233) Aug 2011 Aug 2014
TA232 Epilepsy (partial) - retigabine (adjuvant) (TA232) Jul 2011 Jun 2014
TA231 Depression - agomelatine (terminated appraisal) (TA231) Jul 2011 TBC
TA230 Myocardial infarction (persistent ST-segment elevation) - bivalirudin (TA230) Jul 2011 Jul 2014
TA229 Macular oedema (retinal vein occlusion) - dexamethasone (TA229) Jul 2011 Jan 2014
TA228 Multiple myeloma (first line) - bortezomib and thalidomide (TA228) Jul 2011 Jul 2014
TA227 Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy) (TA227) Jun 2011 Apr 2013
TA226 Lymphoma (follicular non-Hodgkin's) - rituximab (TA226) Jun 2011 May 2014
TA225 Rheumatoid arthritis (after the failure of previous anti-rheumatic drugs) - golimumab (TA225) Jun 2011 Jun 2013
TA224 Rheumatoid arthritis (methotrexate-naïve) - golimumab (terminated appraisal) (TA224) Jun 2011 TBC
TA223 Peripheral arterial disease - cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate (TA223) May 2011 May 2014
TA222 Ovarian cancer (relapsed) - trabectedin (TA222) Apr 2011 TBC
TA221 Thrombocytopenic purpura - romiplostim (TA221) Apr 2011 Mar 2014
TA220 Psoriatic arthritis - golimumab (TA220) Apr 2011 Jun 2013
TA219 Everolimus for the second-line treatment of advanced renal cell carcinoma (TA219) Apr 2011 Feb 2013
TA218 Myelodysplastic syndromes - azacitidine (TA218) Mar 2011 Feb 2014
TA217 Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (TA217) Mar 2011 Apr 2014
TA216 Leukaemia (lymphocytic) - bendamustine (TA216) Feb 2011 Dec 2013
TA215 Renal cell carcinoma (first line metastatic) - pazopanib (TA215) Feb 2011 Dec 2013
TA214 Breast cancer - bevacizumab (in combination with a taxane) (TA214) Feb 2011 Jul 2013
TA213 Schizophrenia - aripiprazole (TA213) Jan 2011 Nov 2013
TA212 Colorectal cancer (metastatic) - bevacizumab (TA212) Dec 2010 May 2013
TA211 Constipation (women) - prucalopride (TA211) Dec 2010 Oct 2013
TA210 Vascular disease - clopidogrel and dipyridamole (TA210) Dec 2010 Jul 2013
TA209 Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib (TA209) Nov 2010 Aug 2013
TA208 Gastric cancer (HER2-positive metastatic) - trastuzumab (TA208) Nov 2010 Aug 2013
TA207 Mantle cell lymphoma (relapsed) - temsirolimus (terminated appraisal) (TA207) Oct 2010 TBC
TA206 Lymphoma (non-Hodgkin's) - bendamustine (terminated appraisal) (TA206) Oct 2010 TBC
TA205 Thrombocytopenic purpura - eltrombopag (TA205) (replaced by TA293) Oct 2010 Jun 2013
TA204 Osteoporotic fractures - denosumab (TA204) Oct 2010 TBC
TA203 Diabetes (type 2) - liraglutide (TA203) Oct 2010 May 2012
TA202 Chronic lymphocytic leukaemia - ofatumumab (TA202) Oct 2010 Sep 2013
TA201 Asthma (in children) - omalizumab (TA201) (replaced by TA278) Oct 2010 Oct 2010
TA200 Hepatitis C - peginterferon alfa and ribavirin (TA200) Sep 2010 Jul 2013
TA199 Psoriatic arthritis - etanercept, infliximab and adalimumab (TA199) Aug 2010 Jun 2013
TA198 Rheumatoid arthritis - tocilizumab (TA198) (replaced by TA247) Aug 2010 Aug 2013
TA197 Atrial fibrillation - dronedarone (TA197) Aug 2010 Mar 2013
TA196 Gastrointestinal stromal tumours - imatinib (adjuvant) (TA196) Aug 2010 Jun 2011
TA195 Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor (TA195) Aug 2010 Jun 2013
TA194 Bone loss (therapy-induced) in non-metastatic prostate cancer - denosumab (terminated appraisal) (TA194) (replaced by CG175) Jul 2010 TBC
TA193 Leukaemia (chronic lymphocytic, relapsed) - rituximab (TA193) Jul 2010 TBC
TA192 Lung cancer (non-small-cell, first line) - gefitinib (TA192) Jul 2010 TBC
TA191 Gastric cancer (advanced) - capecitabine (TA191) Jul 2010 May 2013
TA190 Lung cancer (non-small-cell) - pemetrexed (maintenance) (TA190) Jun 2010 TBC
TA189 Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line) (TA189) May 2010 Nov 2012
TA188 Human growth hormone (somatropin) for the treatment of growth failure in children (review) (TA188) May 2010 May 2013
TA187 Crohn's disease - infliximab (review) and adalimumab (review of TA40) (TA187) May 2010 TBC
TA186 Rheumatoid arthritis - certolizumab pegol (TA186) Feb 2010 Sep 2010
TA185 Soft tissue sarcoma - trabectedin (TA185) Feb 2010 Feb 2013
TA184 Lung cancer (small-cell) - topotecan (TA184) Nov 2009 Nov 2012
TA183 Cervical cancer (recurrent) - topotecan (TA183) Oct 2009 Sep 2012
TA182 Acute coronary syndrome - prasugrel (TA182) Oct 2009 Jan 2012
TA181 Lung cancer (non-small-cell, first line treatment) - pemetrexed (TA181) Sep 2009 TBC
TA180 Psoriasis - ustekinumab (TA180) Sep 2009 Jan 2010
TA179 Gastrointestinal stromal tumours - sunitinib (TA179) Sep 2009 Aug 2011
TA178 Renal cell carcinoma (TA178) Aug 2009 Jun 2011
TA177 Eczema (chronic) - alitretinoin (TA177) Aug 2009 Aug 2012
TA176 Colorectal cancer (first line) - cetuximab (TA176) Aug 2009 Aug 2012
TA175 Lung cancer (non-small-cell, second line) - gefitinib (terminated appraisal) (TA175) Jul 2009 TBC
TA174 Leukaemia (chronic lymphocytic, first line) - rituximab (TA174) Jul 2009 TBC
TA173 Hepatitis B - tenofovir disoproxil fumarate (TA173) Jul 2009 Mar 2012
TA172 Head and neck cancer (squamous cell carcinoma) - cetuximab (TA172) Jun 2009 Jun 2012
TA171 Multiple myeloma - lenalidomide (TA171) Jun 2009 Feb 2012
TA170 Venous thromboembolism - rivaroxaban (TA170) Apr 2009 Feb 2012
TA169 Renal cell carcinoma - sunitinib (TA169) Mar 2009 Feb 2011
TA168 Influenza - zanamivir, amantadine and oseltamivir (review) (TA168) Feb 2009 Nov 2013
TA167 Abdominal aortic aneurysm - endovascular stent-grafts (TA167) Feb 2009 Jan 2012
TA166 Hearing impairment - cochlear implants (TA166) Jan 2009 TBC
TA165 Organ preservation (renal) - machine perfusion and static storage (TA165) Nov 2008 TBC
TA164 Hyperuricaemia - febuxostat (TA164) Dec 2008 TBC
TA163 Ulcerative colitis (acute exacerbations) - infliximab (TA163) Dec 2008 TBC
TA162 Lung cancer (non-small-cell) - erlotinib (TA162) Nov 2008 Jun 2010
TA161 Osteoporosis - secondary prevention including strontium ranelate (TA161) Jan 2011 TBC
TA160 Osteoporosis - primary prevention (TA160) Jan 2011 Jul 2010
TA159 Pain (chronic neuropathic or ischaemic) - spinal cord stimulation (TA159) Oct 2008 Nov 2011
TA158 Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir (TA158) Sep 2008 Sep 2011
TA157 Venous thromboembolism - dabigatran (TA157) Sep 2008 TBC
TA156 Pregnancy (rhesus negative women) - routine anti-D (review) (TA156) Aug 2008 TBC
TA155 Macular degeneration (age-related) - ranibizumab and pegaptanib (TA155) Aug 2008 Feb 2014
TA154 Hepatitis B - telbivudine (TA154) Aug 2008 Mar 2012
TA153 Hepatitis B - entecavir (TA153) Aug 2008 Mar 2012
TA152 Coronary artery disease - drug-eluting stents (TA152) Jul 2008 TBC
TA151 Diabetes - insulin pump therapy (TA151) Jul 2008 TBC
TA150 Colorectal cancer (metastatic) - cetuximab (terminated appraisal) (TA150) (replaced by TA242) Jun 2008 TBC
TA149 Glioma (recurrent) - carmustine implants (terminated appraisal) (TA149) Jun 2008 TBC
TA148 Lung cancer (non-small-cell) - bevacizumab (terminated appraisal) (TA148) Jun 2008 TBC
TA147 Breast cancer (advanced & metastatic) - bevacizumab (withdrawn) (TA147) Jun 2008 TBC
TA146 Psoriasis - adalimumab (TA146) Jun 2008 Jul 2008
TA145 Head and neck cancer - cetuximab (TA145) Jun 2008 TBC
TA144 Obesity - rimonabant (withdrawn) (TA144) (withdrawn) Jun 2008 Apr 2010
TA143 Ankylosing spondylitis - adalimumab, etanercept and infliximab (TA143) May 2008 TBC
TA142 Anaemia (cancer-treatment induced) - erythropoietin (alfa and beta) and darbepoetin (TA142) May 2008 TBC
TA141 Rheumatoid arthritis (refractory) - abatacept (TA141) (replaced by TA195) Apr 2008 Jul 2010
TA140 Ulcerative colitis (subacute manifestations) - infliximab (TA140) Apr 2008 TBC
TA139 Sleep apnoea - continuous positive airway pressure (CPAP) (TA139) Mar 2008 TBC
TA138 Asthma (in adults) - corticosteroids (TA138) Mar 2008 Nov 2012
TA137 Lymphoma (follicular non-Hodgkin's) - rituximab (TA137) Feb 2008 TBC
TA136 Structural neuroimaging in first-episode psychosis (TA136) Feb 2008 TBC
TA135 Mesothelioma - pemetrexed disodium (TA135) Jan 2008 TBC
TA134 Psoriasis - infliximab (TA134) Jan 2008 Oct 2008
TA133 Asthma (uncontrolled) - omalizumab (TA133) (replaced by TA278) Nov 2007 TBC
TA132 Hypercholesterolaemia - ezetimibe (TA132) Nov 2007 Oct 2011
TA131 Asthma (in children) - corticosteroids (TA131) Nov 2007 Nov 2012
TA130 Rheumatoid arthritis - adalimumab, etanercept and infliximab (TA130) Oct 2007 Sep 2010
TA129 Multiple myeloma - bortezomib (TA129) Oct 2007 Feb 2012
TA128 Haemorrhoid - stapled haemorroidopexy (TA128) Sep 2007 TBC
TA127 Multiple sclerosis - natalizumab (TA127) Aug 2007 TBC
TA126 Rheumatoid arthritis (refractory) - rituximab (TA126) (replaced by TA195) Aug 2007 Jul 2010
TA125 Psoriatic arthritis (moderate to severe) - adalimumab (TA125) (replaced by TA199) Aug 2007 TBC
TA124 Lung cancer (non-small-cell) - pemetrexed (TA124) Aug 2007 Jan 2010
TA123 Smoking cessation - varenicline (TA123) Jul 2007 TBC
TA122 Ischaemic stroke (acute) - alteplase (TA122) (replaced by TA264) Jun 2007 TBC
TA121 Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide (TA121) Jun 2007 TBC
TA120 Heart failure - cardiac resynchronisation (TA120) May 2007 TBC
TA119 Leukaemia (lymphocytic) - fludarabine (TA119) Feb 2007 Oct 2009
TA118 Colorectal cancer (metastatic) - bevacizumab and cetuximab (TA118) (partially updated by TA242) Jan 2007 May 2009
TA117 Hyperparathyroidism - cinacalcet (TA117) Jan 2007 Dec 2009
TA116 Breast cancer - gemcitabine (TA116) Jan 2007 Jan 2010
TA115 Drug misuse - naltrexone (TA115) Jan 2007 TBC
TA114 Drug misuse - methadone and buprenorphine (TA114) Jan 2007 TBC
TA113 Diabetes (type 1 and 2) - inhaled insulin (withdrawn) (TA113) (withdrawn) Dec 2006 TBC
TA112 Breast cancer (early) - hormonal treatments (TA112) Nov 2006 Jun 2009
TA111 Alzheimer's disease - donepezil, galantamine, rivastigmine (review) and memantine (replaced by TA217) (TA111) (withdrawn) Sep 2007 TBC
TA110 Follicular lymphoma - rituximab (TA110) (replaced by TA243) Sep 2006 Jun 2009
TA109 Breast cancer (early) - docetaxel (TA109) Sep 2006 TBC
TA108 Breast cancer (early) - paclitaxel (TA108) Sep 2006 TBC
TA107 Breast cancer (early) - trastuzumab (TA107) Aug 2006 TBC
TA106 Hepatitis C - peginterferon alfa and ribavirin (TA106) Aug 2006 TBC
TA105 Colorectal cancer - laparoscopic surgery (review) (TA105) Aug 2006 Sep 2009
TA104 Psoriatic arthritis - etanercept and infliximab (TA104) (replaced by TA199) Jul 2006 TBC
TA103 Psoriasis - efalizumab and etanercept (TA103) Jul 2006 TBC
TA102 Conduct disorder in children - parent-training/education programmes (TA102) (replaced by CG158) Jul 2006 TBC
TA101 Prostate cancer (hormone-refractory) - docetaxel (TA101) Jun 2006 Jun 2009
TA100 Colon cancer (adjuvant) - capecitabine and oxaliplatin (TA100) Apr 2006 TBC
TA99 Renal transplantation - immunosuppressive regimens for children and adolescents (TA99) Apr 2006 Mar 2009
TA98 Attention deficit hyperactivity disorder (ADHD) - methylphenidate, atomoxetine and dexamfetamine (review) (TA98) Mar 2006 TBC
TA97 Depression and anxiety - computerised cognitive behavioural therapy (CCBT) (TA97) Feb 2006 TBC
TA96 Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alfa-2a (TA96) (partially updated by CG165) Feb 2006 TBC
TA95 Arrhythmia - implantable cardioverter defibrillators (ICDs) (review) (TA95) Jan 2006 TBC
TA94 Cardiovascular disease - statins (TA94) Jan 2006 TBC
TA93 Colorectal cancer (advanced) - irinotecan, oxaliplatin and raltitrexed (TA93) (replaced by CG131) Aug 2005 Aug 2008
TA92 Tooth decay - HealOzone (TA92) Jul 2005 TBC
TA91 Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (review) (TA91) May 2005 TBC
TA90 Vascular disease - clopidogrel and dipyridamole (TA90) (replaced by TA210) May 2005 TBC
TA89 Cartilage injury - autologous chondrocyte implantation (ACI) (review) (TA89) May 2005 Jan 2012
TA88 Bradycardia - dual chamber pacemakers (TA88) Feb 2005 TBC
TA87 Osteoporosis - secondary prevention (TA87) (replaced by TA161) (withdrawn) Jan 2005 TBC
TA86 Gastrointestinal stromal tumours - imatinib (TA86) Oct 2004 TBC
TA85 Renal transplantation - immuno-suppressive regimens (adults) (TA85) Sep 2004 TBC
TA84 Sepsis (severe) - drotrecogin (withdrawn) (TA84) (withdrawn) Sep 2004 TBC
TA83 Hernia - laparoscopic surgery (review) (TA83) Sep 2004 TBC
TA82 Atopic dermatitis (eczema) - pimecrolimus and tacrolimus (TA82) Aug 2004 Jan 2009
TA81 Atopic dermatitis (eczema) - topical steroids (TA81) Aug 2004 TBC
TA80 Acute coronary syndromes - clopidogrel (TA80) Jul 2004 TBC
TA79 Epilepsy (children) - newer drugs (TA79) (replaced by CG137) Apr 2004 Dec 2006
TA78 Menstrual bleeding - fluid-filled thermal balloon and microwave endometrial ablation (TA78) Apr 2004 TBC
TA77 Insomnia - newer hypnotic drugs (TA77) Apr 2004 TBC
TA76 Epilepsy (adults) - newer drugs (TA76) (replaced by CG137) Mar 2004 Dec 2006
TA75 Hepatitis C - pegylated interferons, ribavirin and alfa interferon (TA75) Jan 2004 TBC
TA74 Trauma - fluid replacement therapy (TA74) Jan 2004 TBC
TA73 Angina and myocardial infarction - myocardial perfusion scintigraphy (TA73) Nov 2003 TBC
TA72 Rheumatoid arthritis - anakinra (TA72) (replaced by CG79) (withdrawn) Nov 2003 TBC
TA71 Ischaemic heart disease - coronary artery stents (TA71) Oct 2003 Nov 2004
TA70 Leukaemia (chronic myeloid) - imatinib (TA70) (partially updated by TA241 and TA251) Oct 2003 Sep 2006
TA69 Cervical cancer - cervical screening (review) (TA69) Oct 2003 TBC
TA68 Macular degeneration (age-related) - photodynamic therapy (TA68) Sep 2003 Feb 2012
TA67 Flu prevention - amantadine and oseltamivir (TA67) (replaced by TA158) Sep 2003 TBC
TA66 Bipolar disorder - new drugs (TA66) (replaced by CG38) (withdrawn) Sep 2003 TBC
TA65 Non-Hodgkin's lymphoma - rituximab (TA65) Sep 2003 Aug 2006
TA64 Growth hormone deficiency (adults) - human growth hormone (TA64) Aug 2003 TBC
TA63 Diabetes (type 2) - glitazones (TA63) (replaced by CG66) (withdrawn) Aug 2003 TBC
TA62 Breast cancer - capecitabine (TA62) (replaced by CG81) May 2003 TBC
TA61 Colorectal cancer - capecitabine and tegafur uracil (TA61) May 2003 TBC
TA60 Diabetes (types 1 and 2) - patient education models (TA60) Apr 2003 Feb 2006
TA59 Electroconvulsive therapy (ECT) (TA59) Apr 2003 TBC
TA58 Flu treatment - zanamivir (review), amantadine and oseltamivir (TA58) (replaced by TA168) (withdrawn) Feb 2003 TBC
TA57 Diabetes (type 1) - insulin pump therapy (TA57) (replaced by TA151) (withdrawn) Feb 2003 TBC
TA56 Stress incontinence - tension-free vaginal tape (TA56) (replaced by CG171) (withdrawn) Feb 2003 TBC
TA55 Ovarian cancer - paclitaxel (review) (TA55) Jan 2003 TBC
TA54 Breast cancer - vinorelbine (TA54) (replaced by CG81) Dec 2002 TBC
TA53 Diabetes (types 1 and 2) - long acting insulin analogues (TA53) Dec 2002 Nov 2005
TA52 Myocardial infarction - thrombolysis (TA52) Oct 2002 TBC
TA51 Depression and anxiety - computerised cognitive behaviour therapy (CCBT) (TA51) (replaced by TA97) (withdrawn) Oct 2002 TBC
TA50 Leukaemia (chronic myeloid) - imatinib (TA50) (replaced by TA70) (withdrawn) Oct 2002 TBC
TA49 Central venous catheters - ultrasound locating devices (TA49) Sep 2002 TBC
TA48 Renal failure - home versus hospital haemodialysis (TA48) Sep 2002 TBC
TA47 Acute coronary syndromes - glycoprotein IIb/IIIa inhibitors (review) (TA47) (partially updated by CG94) Sep 2002 TBC
TA46 Obesity (morbid) - surgery (TA46) (replaced by CG43) (withdrawn) Jul 2002 TBC
TA45 Ovarian cancer (advanced) - pegylated liposomal doxorubicin hydrochloride (TA45) (replaced by TA91) (withdrawn) Jul 2002 TBC
TA44 Hip disease - metal on metal hip resurfacing (TA44) (replaced by TA304) Jun 2002 TBC
TA43 Schizophrenia - atypical antipsychotics (TA43) (replaced by CG82) Jun 2002 TBC
TA42 Growth hormone deficiency (children) - human growth hormone (TA42) (replaced by TA188) May 2002 Jun 2005
TA41 Pregnancy - routine anti-D prophylaxis for RhD-negative women (TA41) (replaced by TA156) (withdrawn) May 2002 TBC
TA40 Crohn's disease - infliximab (TA40) (replaced by TA187) Apr 2002 May 2005
TA39 Smoking cessation - bupropion and nicotine replacement therapy (TA39) (replaced by PH10) (withdrawn) Mar 2002 TBC
TA38 Asthma (older children) - inhaler devices (TA38) Mar 2002 TBC
TA37 Lymphoma (follicular non-Hodgkin's) - rituximab (TA37) (replaced by TA137) Mar 2002 TBC
TA36 Rheumatoid arthritis - etanercept and infliximab (TA36) (replaced by TA130 and TA195) Mar 2002 TBC
TA35 Arthritis (juvenile idiopathic) - etanercept (TA35) Mar 2002 TBC
TA34 Breast cancer - trastuzumab (TA34) Mar 2002 TBC
TA33 Colorectal cancer (advanced) - irinotecan, oxaliplatin & raltitrexed (TA33) (replaced by TA93) (withdrawn) Mar 2002 TBC
TA32 Multiple sclerosis - beta interferon and glatiramer acetate (TA32) Jan 2002 TBC
TA31 Obesity - sibutramine (TA31) (replaced by CG43) (withdrawn) Oct 2001 TBC
TA30 Breast cancer - taxanes (review) (TA30) (replaced by CG81) Sep 2001 TBC
TA29 Leukaemia (lymphocytic) - fludarabine (TA29) Sep 2001 TBC
TA28 Ovarian cancer - topotecan (TA28) (replaced by TA91) (withdrawn) Jul 2001 TBC
TA27 Osteoarthritis and rheumatoid arthritis - cox II inhibitors (TA27) (replaced by CG59 and CG79) (withdrawn) Jul 2001 TBC
TA26 Lung cancer - docetaxel, paclitaxel, gemcitabine and vinorelbine (TA26) (replaced by CG24) Jun 2001 TBC
TA25 Pancreatic cancer - gemcitabine (TA25) May 2001 TBC
TA24 Wound care - debriding agents (TA24) (replaced by CG74) Apr 2001 TBC
TA23 Brain cancer - temozolomide (TA23) Apr 2001 TBC
TA22 Obesity - orlistat (TA22) (replaced by CG43) (withdrawn) Mar 2001 TBC
TA21 Diabetes (type 2) - pioglitazone (TA21) (replaced by TA63) (withdrawn) Mar 2001 TBC
TA20 Motor neurone disease - riluzole (TA20) Jan 2001 TBC
TA19 Alzheimer's disease - donepezil, rivastigmine and galantamine (TA19) (replaced by TA111) (withdrawn) Jan 2001 TBC
TA18 Hernia (inguinal) - laparoscopic surgery (TA18) (replaced by TA83) (withdrawn) Jan 2001 TBC
TA17 Colorectal cancer - laparoscopic surgery (TA17) (replaced by TA105) Dec 2000 TBC
TA16 Knee joints (defective) - autologous cartilage transplantation (TA16) (replaced by TA89) (withdrawn) Dec 2000 TBC
TA15 Flu - zanamivir (TA15) (replaced by TA58) (withdrawn) Nov 2000 TBC
TA14 Hepatitis C - alpha interferon and ribavirin (TA14) (replaced by TA75) (withdrawn) Oct 2000 TBC
TA13 Attention deficit hyperactivity disorder (ADHD) - methylphenidate (TA13) (replaced by TA98) (withdrawn) Oct 2000 TBC
TA12 Acute coronary syndromes - glycoprotein IIb/IIIa inhibitors (TA12) (replaced by TA47) (withdrawn) Sep 2000 TBC
TA11 Arrhythmias - implantable cardioverter defibrillators (ICDs) (TA11) (replaced by TA95) (withdrawn) Sep 2000 TBC
TA10 Asthma (children under 5) - inhaler devices (TA10) Aug 2000 TBC
TA9 Diabetes (type 2) - rosiglitazone (TA9) (replaced by TA63) (withdrawn) Aug 2000 TBC
TA8 Hearing disability - hearing aids (withdrawn) (TA8) (withdrawn) Jul 2000 TBC
TA7 Dyspepsia - proton pump inhibitors (TA7) (replaced by CG17) (withdrawn) Jul 2000 TBC
TA6 Breast cancer - taxanes (TA6) (replaced by TA30) (withdrawn) Jun 2000 TBC
TA5 Cervical cancer - liquid based cytology (TA5) (replaced by TA69) (withdrawn) Jun 2000 TBC
TA4 Ischaemic heart disease - coronary artery stents (TA4) (replaced by TA71) (withdrawn) May 2000 TBC
TA3 Ovarian cancer - taxanes (TA3) (replaced by TA55) (withdrawn) May 2000 TBC
TA2 Hip disease - replacement prostheses (TA2) (replaced by TA304) Apr 2000 May 2011
TA1 Wisdom teeth - removal (TA1) Mar 2000 TBC

This page was last updated: 23 April 2014

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.